Rallybio Corporation RLYB 深 滬
已收盤 02-06 16:00:00 美东时间
4.75
+0.099
+2.12%
華盛通- 最 高5.37
- 今 開4.70
- 成交量 8.27万股
- 最 低 4.41
- 昨 收 4.6512
- 總市值 2.01亿
- 52周最高 5.37
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 0.2201
- 委 比 33.33%
- 總股本 4224.38万
- 歷史最高 25.78
- 量 比 0.44
- 振 幅 20.64%
- 歷史最低 0.2201
- 每 手 1
- 風險率 1.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rallybio Announces 1-For-8 Reverse Stock Split
Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate
02-04 05:59
Rallybio Executes 1-for-8 Reverse Stock Split
Rallybio Executes 1-for-8 Reverse Stock Split Rallybio Corporation will implement a one-for-eight reverse stock split of its common stock, effective February 6, 2026. The move aims to increase the per share trading price and help maintain its listing on the Nasdaq Capital Market. After the split, Ra
02-04 05:05
Rallybio führt Aktiensplit im Verhältnis 1:8 durch
Rallybio führt Aktiensplit im Verhältnis 1:8 durch Die Rallybio Corporation führt einen Reverse Stock Split im Verhältnis 1:8 durch. Die Maßnahme tritt am 6. Februar 2026 in Kraft und soll den Aktienkurs anheben, um die Anforderungen für die Notierung am Nasdaq Capital Market zu erfüllen. Die Aktie
02-04 05:05
Rallybio Corporation Held Special Shareholder Meeting
Rallybio Corporation Held Special Shareholder Meeting Rallybio Corporation held a special meeting of stockholders on January 26, 2026. Stockholders voted to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the company's issued and outstanding common stock a
01-30 06:15
Rallybio Q3 EPS $0.36 Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
Rallybio (NASDAQ:RLYB) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.21) by 269.01 percent. This is a 238.46 percent increase over losses of $(0.26) per share from the
2025-11-06 21:25
Rallybio Completes Dosing For First Cohort In Phase 1 Confirmatory PK/PD Study Of RLYB116 Its Once-Weekly, Small-Volume, Subcutaneous C5 Inhibitor Being Developed To Treat Rare Diseases
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluat
2025-09-25 20:05
Rallybio shares are trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
Rallybio shares are trading higher after the company received a $12.5M equity m...
2025-09-03 20:02
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
2025-07-08 21:44
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Rallybio stock soared on Tuesday after the company reached an agreement with Re...
2025-07-08 21:12
Recursion Acquires Rallybio's Full Interest In Joint ENPP1 Inhibitor Program And Associated Backup Molecule For Treatment Of Hypophosphatasia; Rallybio To Receive $7.5M Upfront, With Potential For $17.5M More In Preclinical And Clinical Milestones
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor
2025-07-08 20:04
